A head-to-head comparison of in-person, virtual and artificial intelligence-augmented assessments of psoriasis disease severity went online in the Journal of Investigative Dermatology on 8 October 2026. The study sets out to answer a question every busy psoriasis clinic now faces: can a machine-assisted read match a trained dermatologist's eyes?

The trial comes at a moment when telehealth has become routine and AI tools are moving from proof-of-concept to bedside. Psoriasis severity scoring has always depended on the clinician's judgment — the PASI and its cousins reward experience, and they punish inconsistency. Remote visits and automated image analysis promise scalability. What they have lacked, until now, is rigorous side-by-side validation against the gold standard of an in-person exam.

Who ran the study, and how was it built?

The author list reads like a Canadian psoriasis network. R. Bissonnette, M. Gooderham, R. Vender and C. Maari lead a group that also includes E. Saint-Cyr Proulx, A. Palijan and P. Jahl, alongside B. Betz-Stablein, B. D'Alessandro and A. Melione — a mix of clinical investigators and computational scientists. That combination matters. Comparing three assessment modalities in one protocol demands both dermatology depth and AI engineering.

The design, as the title states, is a three-way comparison: the same patients' disease severity evaluated in person, evaluated virtually, and evaluated with AI augmentation. The Journal of Investigative Dermatology, one of the field's highest-impact research titles, published the full methodology and results on 8 October 2026.

Why does this comparison matter for practice?

Psoriasis care has leaned hard on remote delivery since 2020. Yet severity assessment drives treatment decisions — biologic escalation, dose adjustment, trial eligibility. If a virtual or AI-augmented read diverges from the bedside read, patients can be over- or under-treated. If the modalities agree, clinics gain a defensible way to extend reach without sacrificing measurement quality.

That's the practical stake. The study does not simply ask whether AI looks impressive. It asks whether AI-augmented scoring lands close enough to the in-person standard that clinicians can act on it.

What should readers watch next?

Derm Field readers will want the full text's numbers — concordance metrics, PASI-based agreement and any subgroup differences across severity ranges. The 8 October 2026 online publication gives the field a reference point for how these three modalities stack up in a controlled comparison, and subsequent validation in routine clinics, rather than trial settings, will determine whether AI-augmented psoriasis scoring earns a permanent place in the workflow.